PH12014502468A1 - Methods for identifying immunobinders of cell-surface antigens - Google Patents
Methods for identifying immunobinders of cell-surface antigensInfo
- Publication number
- PH12014502468A1 PH12014502468A1 PH12014502468A PH12014502468A PH12014502468A1 PH 12014502468 A1 PH12014502468 A1 PH 12014502468A1 PH 12014502468 A PH12014502468 A PH 12014502468A PH 12014502468 A PH12014502468 A PH 12014502468A PH 12014502468 A1 PH12014502468 A1 PH 12014502468A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- surface antigens
- cell
- immunobinders
- identifying
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/5052—Cells of the immune system involving B-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15510509P | 2009-02-24 | 2009-02-24 | |
US15504109P | 2009-02-24 | 2009-02-24 | |
CH8322009 | 2009-06-02 | ||
PCT/CH2009/000222 WO2009155726A2 (en) | 2008-06-25 | 2009-06-25 | Humanization of rabbit antibodies using a universal antibody framework |
PCT/CH2010/000044 WO2010096941A1 (en) | 2009-02-24 | 2010-02-22 | Methods for identifying immunobinders of cell-surface antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
PH12014502468A1 true PH12014502468A1 (en) | 2016-01-18 |
PH12014502468B1 PH12014502468B1 (en) | 2016-01-18 |
Family
ID=48917567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12014502468A PH12014502468B1 (en) | 2009-02-24 | 2014-11-05 | Methods for identifying immunobinders of cell-surface antigens |
Country Status (12)
Country | Link |
---|---|
JP (3) | JP6161655B2 (zh) |
KR (4) | KR20180005752A (zh) |
CN (1) | CN105116138A (zh) |
BR (1) | BRPI1005398A2 (zh) |
CL (1) | CL2011001453A1 (zh) |
ES (1) | ES2618181T3 (zh) |
IL (4) | IL226955A (zh) |
MX (1) | MX352922B (zh) |
PH (1) | PH12014502468B1 (zh) |
RU (2) | RU2577965C2 (zh) |
SG (3) | SG10201408247SA (zh) |
ZA (1) | ZA201103125B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110016462B (zh) * | 2019-02-20 | 2020-04-24 | 优睿赛思(武汉)生物科技有限公司 | 从脾脏细胞中高效分离单个抗原特异性b淋巴细胞的方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63253098A (ja) * | 1987-04-10 | 1988-10-20 | Ube Ind Ltd | ヒト抗体に対するモノクロ−ナル抗体、その製法及び用途 |
IL91948A (en) | 1988-10-26 | 1994-05-30 | Immunomedics | Removal of immunoreactive components from a sample |
US5417972A (en) * | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
KR0119909B1 (ko) * | 1993-10-05 | 1997-10-20 | 김은영 | 플로우 사이토미터를 이용한 고상형 면역 측정방법 |
CA2761116A1 (en) * | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
WO1998002462A1 (en) * | 1996-07-16 | 1998-01-22 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Immunoglobulin superfamily domains and fragments with increased solubility |
CN105175535A (zh) * | 2002-05-22 | 2015-12-23 | 艾斯巴技术-诺华有限责任公司 | 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 |
CN1396182A (zh) * | 2002-07-31 | 2003-02-12 | 陕西超英生物医学研究开发有限公司 | 人内皮生长因子受体2蛋白全人单克隆抗体及其制备方法 |
EP1539947A4 (en) * | 2002-08-15 | 2006-09-06 | Epitomics Inc | HUMANIZED RABBIT ANTIBODIES |
AU2003298112A1 (en) * | 2002-11-13 | 2004-06-03 | Micromet Ag | Method for identifying antigen specific b cells |
JP4336812B2 (ja) * | 2003-03-07 | 2009-09-30 | 博夫 岩田 | 細胞に発現する表面抗原を迅速に同定するための分析方法 |
WO2004102198A2 (en) * | 2003-05-15 | 2004-11-25 | Cytos Biotechnology Ag | Selection of b cells with specificity of interest: method of preparation and use |
EP1651659A4 (en) * | 2003-08-07 | 2008-09-17 | Epitomics Inc | METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES |
US8945857B2 (en) * | 2005-07-01 | 2015-02-03 | John Schrader | Methods of isolating cells and generating monoclonal antibodies |
US20070134249A1 (en) * | 2005-12-08 | 2007-06-14 | Genitope Corporation | Combination therapy and antibody panels |
KR101363695B1 (ko) * | 2005-12-28 | 2014-02-14 | 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 | 항페리오스틴에 대한 항체, 및 페리오스틴이 관여하는 질환의 예방 또는 치료를 위해 그것을 함유하는 약제학적 조성물 |
US7582298B2 (en) * | 2006-06-02 | 2009-09-01 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
WO2008004834A1 (en) * | 2006-07-06 | 2008-01-10 | Isu Abxis Co., Ltd | Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor |
-
2010
- 2010-02-22 BR BRPI1005398-0A patent/BRPI1005398A2/pt not_active Application Discontinuation
- 2010-02-22 SG SG10201408247SA patent/SG10201408247SA/en unknown
- 2010-02-22 KR KR1020187000320A patent/KR20180005752A/ko active Application Filing
- 2010-02-22 CN CN201510261116.5A patent/CN105116138A/zh active Pending
- 2010-02-22 SG SG2014014864A patent/SG2014014864A/en unknown
- 2010-02-22 SG SG10201708233VA patent/SG10201708233VA/en unknown
- 2010-02-22 RU RU2011124039/10A patent/RU2577965C2/ru active
- 2010-02-22 KR KR1020167035683A patent/KR101817279B1/ko active IP Right Grant
- 2010-02-22 KR KR1020197005221A patent/KR102059866B1/ko active IP Right Grant
- 2010-02-22 ES ES10705086.6T patent/ES2618181T3/es active Active
- 2010-02-22 KR KR1020167003693A patent/KR101689791B1/ko active IP Right Grant
- 2010-02-22 MX MX2015017453A patent/MX352922B/es unknown
-
2011
- 2011-04-28 ZA ZA2011/03125A patent/ZA201103125B/en unknown
- 2011-06-15 CL CL2011001453A patent/CL2011001453A1/es unknown
-
2013
- 2013-06-13 IL IL226955A patent/IL226955A/en active IP Right Grant
- 2013-06-13 IL IL226956A patent/IL226956A/en active IP Right Grant
-
2014
- 2014-11-05 PH PH12014502468A patent/PH12014502468B1/en unknown
-
2015
- 2015-03-26 IL IL237985A patent/IL237985B/en active IP Right Grant
- 2015-05-19 JP JP2015101581A patent/JP6161655B2/ja active Active
-
2017
- 2017-04-28 JP JP2017090650A patent/JP6604989B2/ja not_active Expired - Fee Related
- 2017-10-09 RU RU2017135831A patent/RU2017135831A/ru not_active Application Discontinuation
-
2018
- 2018-09-14 JP JP2018172287A patent/JP2018196395A/ja active Pending
- 2018-11-20 IL IL26315818A patent/IL263158B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
RU2577965C2 (ru) | 2016-03-20 |
CL2011001453A1 (es) | 2012-02-24 |
BRPI1005398A2 (pt) | 2019-03-26 |
JP2017192384A (ja) | 2017-10-26 |
JP2018196395A (ja) | 2018-12-13 |
IL263158B (en) | 2019-10-31 |
ES2618181T3 (es) | 2017-06-21 |
KR20180005752A (ko) | 2018-01-16 |
RU2011124039A (ru) | 2012-12-20 |
KR101817279B1 (ko) | 2018-01-10 |
IL226955A0 (en) | 2013-07-31 |
IL226956A (en) | 2015-04-30 |
RU2017135831A (ru) | 2019-04-09 |
SG10201708233VA (en) | 2017-11-29 |
MX352922B (es) | 2017-12-14 |
KR20160150642A (ko) | 2016-12-30 |
SG10201408247SA (en) | 2015-02-27 |
SG2014014864A (en) | 2014-09-26 |
KR20190020202A (ko) | 2019-02-27 |
RU2017135831A3 (zh) | 2019-04-09 |
PH12014502468B1 (en) | 2016-01-18 |
CN105116138A (zh) | 2015-12-02 |
IL226955A (en) | 2015-04-30 |
KR101689791B1 (ko) | 2016-12-26 |
JP6161655B2 (ja) | 2017-07-12 |
ZA201103125B (en) | 2012-08-29 |
KR20160022397A (ko) | 2016-02-29 |
IL263158A (en) | 2018-12-31 |
JP2015146825A (ja) | 2015-08-20 |
IL237985B (en) | 2018-12-31 |
JP6604989B2 (ja) | 2019-11-13 |
IL226956A0 (en) | 2013-07-31 |
KR102059866B1 (ko) | 2019-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1245802A1 (zh) | 多特異性抗體、抗體類似物、組合物和方法 | |
CY1121208T1 (el) | Σκευασματα αντισωματος ναταλιζουμαμπης | |
PH12013502230A1 (en) | Multispecific antibodies | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
UA104459C2 (uk) | Антитіла проти fgfr3 і способи їх застосування | |
MX2012007340A (es) | Anticuerpos anti/her3 y usos de los mismos. | |
TN2010000213A1 (en) | Wise binding antibodies and epitopes | |
MX2013009362A (es) | Anticuerpo contra el csf-1r. | |
UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
MY162791A (en) | Anti-il-23 antibodies | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
MX2011010012A (es) | NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS. | |
MX2011011925A (es) | Anticuerpos triespecificos o tetraespecificos. | |
WO2009112245A9 (en) | Antibody against the csf-1 r | |
MX2009004167A (es) | Anticuerpos que enlazan epitopos cxcr7. | |
MX340555B (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
JO3437B1 (ar) | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها | |
MX340683B (es) | Anticuerpos anti-vla-4. | |
WO2010136483A3 (en) | Antigen-binding proteins | |
MX2013002960A (es) | Composiciones de anticuerpo y metodos de uso. | |
WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
MX350807B (es) | Composiciones y metodos para el analisis de cancer de prostata. |